JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment On Monday, financial services firm JP Morgan (NYSE:JPM) continued its coverage of clinical-stage biotech company Allogene Therapeutics (NASDAQ:ALLO), issuing an Overweight recommendation. The one-year price target for Allogene Therapeutics is predicted to average at $17.27, indicating a potential ...
See Details: JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment